e-Poster Presentation Clinical Oncology Society of Australia Annual Scientific Meeting 2020

Health-Related Quality of Life (HRQoL) at final analysis of the SPARTAN study of Apalutamide (APA) vs Placebo (PBO) in patients (pts) with Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) receiving Androgen Deprivation Therapy (ADT) (#237)

Siobhan Ng 1 , Stéphane Oudard 2 , Boris Hadaschik 3 , Fred Saad 4 , David Cella 5 , Ethan Basch 6 , Paul N Mainwaring 7 , Julie N Graff 8 , Shiva Dibaj 9 , Susan Li 10 , Sabine D Brookman-May 11 12 , Peter De Porre 13 , Jeremiah J Trudeau 14 , Eric J Small 15 , Matthew R Smith 16
  1. St John Of God Hospital Subiaco, Perth, WA, Australia
  2. Georges Pompidou Hospital, Paris, France
  3. University of Duisburg-Essen, Essen, and Ruprecht-Karls University Heidelberg, Heidelberg, Germany
  4. Centre Hospitalier de l'Université de Montréal, Université de Montréal, Monteal, Quebec, Canada
  5. Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
  6. University of North Carolina-Chapel Hill, Chapel Hill,, NC, USA
  7. Center for Personalized Nanomedicine, University of Queensland, Brisbane, QLD, Australia
  8. VA Portland Health Care System, Portland and Knight Cancer Institute, Oregon Health & Science University, Potland, OR, USA
  9. Janssen Research & Development, San Diego, CA, USA
  10. Janssen Research & Development, Spring House, PA, USA
  11. Janssen Research & Development, Los Angeles, CA, USA
  12. Ludwig Maximilians University, Munich, Germany
  13. Janssen Research & Development, Beerse, Belgium
  14. Janssen Global Services, , Raritan, NJ, USA
  15. Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA
  16. Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA
Publish consent withheld